title: Progesterone receptor expression is associated with longer overall survival within high-grade histotypes of endometrial carcinoma: A Canadian high risk endometrial cancer consortium (CHREC) study.
abstract: OBJECTIVE
  To assess the association of hormone receptor expression with outcome in high-grade endometrial carcinomas.
  
  
  METHODS
  This study included three sites participating in the Canadian High Risk Endometrial Cancer (CHREC) consortium. Sections from tissue microarrays containing cases with a diagnosis of endometrioid grade 3 (EC3) and endometrial serous carcinoma (ESC) were assessed for estrogen (ER) and progesterone receptor (PR) expression by immunohistochemistry. Expression was considered present if >1% of tumor cell nuclei were labeled. Associations with overall survival were assessed.
  
  
  RESULTS
  ER expression was present in 168/216 (78%) of EC3 and 124/192 (65%) of ESC. PR expression was present in 148/212 (70%) of EC3 and 83/196 (42%) of ESC. PR expression was significantly associated with favorable overall survival in EC3 and ESC (log rank, p=0.018 and p=0.0024) but ER expression was not. PR expression was significantly associated with favorable overall survival in EC3 independent of age, stage, center and lymph-vascular invasion (hazard ratio=0.457, 95% CI 0.257-0.811, p=0.0075) as well as in stage I and II ESC (hazard ratio=0.266, 95% CI 0.094-0.750, p=0.0123).
  
  
  CONCLUSIONS
  Our data provide support for the assessment of the PR expression status in EC3 and ESC. Future work will be required to determine how PR expression may be incorporated into management of patients with EC3 and ESC.
authors.affiliation: Department of Pathology and Laboratory Medicine, University of Calgary, Canada. Electronic address: martin.koebel@cls.ab.ca.
authors.forename: Martin
authors.initials: M
authors.lastname: Köbel
authors.affiliation: Biostatistics Department, Princess Margaret Cancer Centre, Canada; Division of Biostatistics, Dalla Lana School of Public Health, University of Toronto, Canada.
authors.forename: Eshetu G
authors.initials: EG
authors.lastname: Atenafu
authors.affiliation: Department of Pathology and Laboratory Medicine, University of Calgary, Canada.
authors.forename: Peter F
authors.initials: PF
authors.lastname: Rambau
authors.affiliation: Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of Toronto, Canada.
authors.forename: Sarah E
authors.initials: SE
authors.lastname: Ferguson
authors.affiliation: Division of Gynecologic Oncology, University of Calgary, Canada.
authors.forename: Gregg S
authors.initials: GS
authors.lastname: Nelson
authors.affiliation: Division of Biostatistics, Dalla Lana School of Public Health, University of Toronto, Canada.
authors.forename: T C
authors.initials: TC
authors.lastname: Ho
authors.affiliation: Biostatistics Department, Princess Margaret Cancer Centre, Canada; Division of Biostatistics, Dalla Lana School of Public Health, University of Toronto, Canada.
authors.forename: Tony
authors.initials: T
authors.lastname: Panzarella
authors.affiliation: Division of Gynecologic Oncology, University of British Columbia, Canada.
authors.forename: Jessica N
authors.initials: JN
authors.lastname: McAlpine
authors.affiliation: Division of Anatomic Pathology, University of British Columbia, Canada.
authors.forename: C Blake
authors.initials: CB
authors.lastname: Gilks
authors.affiliation: Department of Pathology and Laboratory Medicine, University of Toronto, Canada.
authors.forename: Blaise A
authors.initials: BA
authors.lastname: Clarke
authors.affiliation: Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of Toronto, Canada.
authors.forename: Marcus Q
authors.initials: MQ
authors.lastname: Bernardini
mesh_terms: D002170:Canada / Q000453:epidemiology; D018269:Carcinoma, Endometrioid / Q000378:metabolism* / Q000401:mortality / Q000473:pathology*; D015331:Cohort Studies; D016889:Endometrial Neoplasms / Q000378:metabolism* / Q000401:mortality / Q000473:pathology*; D005260:Female; D006801:Humans; D007150:Immunohistochemistry; D008875:Middle Aged; D060787:Neoplasm Grading; D009367:Neoplasm Staging; D011379:Prognosis; D011960:Receptors, Estrogen / Q000096:biosynthesis; D011980:Receptors, Progesterone / Q000096:biosynthesis*; D012307:Risk Factors; D015996:Survival Rate; D046888:Tissue Array Analysis
chemical_list: D011960:Receptors, Estrogen; D011980:Receptors, Progesterone
keywords: ER; Endometrial cancer; Endometrioid; Highgrade; Hormone receptor; PR; Prognosis; Serous